3SBio Presents Long-Term Phase II NSCLC Trial Results at ESMO 2026
3SBio presented long-term follow-up results from a Chinese Phase II study of SSGJ-707 combined with chemotherapy as first-line treatment for advanced non-small cell lung cancer. The headline reports median progression-free survival approaching 14 months.